Base de dados : MEDLINE
Pesquisa : D20.215.894.899.290.400 [Categoria DeCS]
Referências encontradas : 231 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 24 ir para página                         

  1 / 231 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28378566
[Au] Autor:Zhang J; Liu H; Wei B
[Ad] Endereço:State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China.
[Ti] Título:Immune response of T cells during herpes simplex virus type 1 (HSV-1) infection.
[So] Source:J Zhejiang Univ Sci B;18(4):277-288, 2017 Apr..
[Is] ISSN:1862-1783
[Cp] País de publicação:China
[La] Idioma:eng
[Ab] Resumo:Herpes simplex virus type 1 (HSV-1), a neurotropic member of the alphaherpes virus family, is among the most prevalent and successful human pathogens. HSV-1 can cause serious diseases at every stage of life including fatal disseminated disease in newborns, cold sores, eye disease, and fatal encephalitis in adults. HSV-1 infection can trigger rapid immune responses, and efficient inhibition and clearance of HSV-1 infection rely on both the innate and adaptive immune responses of the host. Multiple strategies have been used to restrict host innate immune responses by HSV-1 to facilitate its infection in host cells. The adaptive immunity of the host plays an important role in inhibiting HSV-1 infections. The activation and regulation of T cells are the important aspects of the adaptive immunity. They play a crucial role in host-mediated immunity and are important for clearing HSV-1. In this review, we examine the findings on T cell immune responses during HSV-1 infection, which hold promise in the design of new vaccine candidates for HSV-1.
[Mh] Termos MeSH primário: Herpes Simples/imunologia
Herpesvirus Humano 1
Linfócitos T/imunologia
[Mh] Termos MeSH secundário: Imunidade Adaptativa
Animais
Linfócitos T CD4-Positivos/imunologia
Linfócitos T CD8-Positivos/imunologia
Sistema Nervoso Central/imunologia
Herpes Simples/prevenção & controle
Vacinas contra o Vírus do Herpes Simples/imunologia
Herpesvirus Humano 1/imunologia
Herpesvirus Humano 1/patogenicidade
Seres Humanos
Imunidade Inata
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Herpes Simplex Virus Vaccines)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170406
[St] Status:MEDLINE
[do] DOI:10.1631/jzus.B1600460


  2 / 231 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28228587
[Au] Autor:Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
[Ad] Endereço:Vaccine Platform Group, MedImmune, Gaithersburg, Maryland, USA henselm@medimmune.com dereksloan@yahoo.com.
[Ti] Título:Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
[So] Source:J Virol;91(9), 2017 May 01.
[Is] ISSN:1098-5514
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Several prophylactic vaccines targeting herpes simplex virus 2 (HSV-2) have failed in the clinic to demonstrate sustained depression of viral shedding or protection from recurrences. Although these vaccines have generated high titers of neutralizing antibodies (NAbs), their induction of robust CD8 T cells has largely been unreported, even though evidence for the importance of HSV-2 antigen-specific CD8 T cells is mounting in animal models and in translational studies involving subjects with active HSV-2-specific immune responses. We developed a subunit vaccine composed of the NAb targets gD and gB and the novel T cell antigen and tegument protein UL40, and we compared this vaccine to a whole-inactivated-virus vaccine (formaldehyde-inactivated HSV-2 [FI-HSV-2]). We evaluated different formulations in combination with several Th1-inducing Toll-like receptor (TLR) agonists In mice, the TLR9 agonist cytosine-phosphate-guanine (CpG) oligodeoxynucleotide formulated in a squalene-based oil-in-water emulsion promoted most robust, functional HSV-2 antigen-specific CD8 T cell responses and high titers of neutralizing antibodies, demonstrating its superiority to vaccines adjuvanted by monophosphoryl lipid A (MPL)-alum. We further established that FI-HSV-2 alone or in combination with adjuvants as well as adjuvanted subunit vaccines were successful in the induction of NAbs and T cell responses in guinea pigs. These immunological responses were coincident with a suppression of vaginal HSV-2 shedding, low lesion scores, and a reduction in latent HSV-2 DNA in dorsal root ganglia to undetectable levels. These data support the further preclinical and clinical development of prophylactic HSV-2 vaccines that contain appropriate antigen and adjuvant components responsible for programming elevated CD8 T cell responses. Millions of people worldwide are infected with herpes simplex virus 2 (HSV-2), and to date, an efficacious prophylactic vaccine has not met the rigors of clinical trials. Attempts to develop a vaccine have focused primarily on glycoproteins necessary for HSV-2 entry as target antigens and to which the dominant neutralizing antibody response is directed during natural infection. Individuals with asymptomatic infection have exhibited T cell responses against specific HSV-2 antigens not observed in symptomatic individuals. We describe for the first time the immunogenicity profile in animal models of UL40, a novel HSV-2 T cell antigen that has been correlated with asymptomatic HSV-2 disease. Additionally, vaccine candidates adjuvanted by a robust formulation of the CpG oligonucleotide delivered in emulsion were superior to unadjuvanted or MPL-alum-adjuvanted formulations at eliciting a robust cell-mediated immune response and blocking the establishment of a latent viral reservoir in the guinea pig challenge model of HSV-2 infection.
[Mh] Termos MeSH primário: Adjuvantes Imunológicos/farmacologia
Anticorpos Neutralizantes/sangue
Anticorpos Antivirais/sangue
Linfócitos T CD8-Positivos/imunologia
Vacinas contra o Vírus do Herpes Simples/imunologia
Herpes Simples/prevenção & controle
Herpesvirus Humano 2/imunologia
Latência Viral/imunologia
[Mh] Termos MeSH secundário: Animais
Anticorpos Neutralizantes/imunologia
Anticorpos Antivirais/imunologia
Antígenos Virais/imunologia
Modelos Animais de Doenças
Feminino
Glicoproteínas/imunologia
Cobaias
Herpes Simples/imunologia
Herpes Simples/virologia
Herpesvirus Humano 2/fisiologia
Imunidade Celular/imunologia
Camundongos
Camundongos Endogâmicos C57BL
Oligodesoxirribonucleotídeos/imunologia
Receptor Toll-Like 9/imunologia
Vacinas de Subunidades/imunologia
Proteínas do Envelope Viral/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adjuvants, Immunologic); 0 (Antibodies, Neutralizing); 0 (Antibodies, Viral); 0 (Antigens, Viral); 0 (Glycoproteins); 0 (Herpes Simplex Virus Vaccines); 0 (Oligodeoxyribonucleotides); 0 (Toll-Like Receptor 9); 0 (Vaccines, Subunit); 0 (Viral Envelope Proteins)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:171122
[Lr] Data última revisão:
171122
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170224
[St] Status:MEDLINE


  3 / 231 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28122977
[Au] Autor:Royer DJ; Carr MM; Chucair-Elliott AJ; Halford WP; Carr DJ
[Ad] Endereço:Department of Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
[Ti] Título:Impact of Type I Interferon on the Safety and Immunogenicity of an Experimental Live-Attenuated Herpes Simplex Virus 1 Vaccine in Mice.
[So] Source:J Virol;91(7), 2017 Apr 01.
[Is] ISSN:1098-5514
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Viral fitness dictates virulence and capacity to evade host immune defenses. Understanding the biological underpinnings of such features is essential for rational vaccine development. We have previously shown that the live-attenuated herpes simplex virus 1 (HSV-1) mutant lacking the nuclear localization signal (NLS) on the ICP0 gene (0ΔNLS) is sensitive to inhibition by interferon beta (IFN-ß) and functions as a highly efficacious experimental vaccine. Here, we characterize the host immune response and pathogenesis of HSV-1 0ΔNLS relative to its fully virulent parental strain in C57BL/6 mice. Additionally, we explore the role of type 1 interferon (IFN-α/ß) signaling on virulence and immunogenicity of HSV-1 0ΔNLS and uncover a probable sex bias in the induction of IFN-α/ß in the cornea during HSV-1 infection. Our data show that HSV-1 0ΔNLS lacks neurovirulence even in highly immunocompromised mice lacking the IFN-α/ß receptor. These studies support the translational viability of the HSV-1 0ΔNLS vaccine strain by demonstrating that, while it is comparable to a virulent parental strain in terms of immunogenicity, HSV-1 0ΔNLS does not induce significant tissue pathology. HSV-1 is a common human pathogen associated with a variety of clinical presentations ranging in severity from periodic "cold sores" to lethal encephalitis. Despite the consistent failures of HSV subunit vaccines in clinical trials spanning the past 28 years, opposition to live-attenuated HSV vaccines predicated on unfounded safety concerns currently limits their widespread acceptance. Here, we demonstrate that a live-attenuated HSV-1 vaccine has great translational potential.
[Mh] Termos MeSH primário: Córnea/metabolismo
Vacinas contra o Vírus do Herpes Simples/imunologia
Herpes Simples/prevenção & controle
Herpesvirus Humano 1/imunologia
Interferon Tipo I/fisiologia
[Mh] Termos MeSH secundário: Imunidade Adaptativa
Animais
Córnea/imunologia
Córnea/virologia
Vacinas contra o Vírus do Herpes Simples/administração & dosagem
Camundongos Endogâmicos C57BL
Camundongos Knockout
Vacinação
Vacinas Atenuadas/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Herpes Simplex Virus Vaccines); 0 (Interferon Type I); 0 (Vaccines, Attenuated)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170913
[Lr] Data última revisão:
170913
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170127
[St] Status:MEDLINE


  4 / 231 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27635861
[Au] Autor:Leplina O; Starostina N; Zheltova O; Ostanin A; Shevela E; Chernykh E
[Ad] Endereço:a Institite of Fundamental and Clinical Immunology , Novosibirsk , Russia.
[Ti] Título:Dendritic cell-based vaccines in treating recurrent herpes labialis: Results of pilot clinical study.
[So] Source:Hum Vaccin Immunother;12(12):3029-3035, 2016 12.
[Is] ISSN:2164-554X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Recurrent herpes simplex labialis caused predominantly with herpes simplexvirus 1(HSV-1) is a major problem, for which various treatments have minimal impact. Given the important role of the immune system in controlling virus infection, an activation of virus-specific immune responses, in particular,using dendritic cell (DCs) vaccines, seems to be a promising approach for the treatment of patients with frequent recurrences of herpes labialis. The current paper presents the results of a pilot study of the safety and efficacy of DC vaccines in 14 patients with recurrent HSV-1 infections. DCs were generated in presence of GM-CSF and IFN-alpha and were loaded with HSV-1 recombinant viral glycoprotein D (HSV1gD). DCs cells were injected subcutaneously as 2 courses of vaccination during 9 months. Immunotherapy with DCs did not induce any serious side effects and resulted in more than 2-fold reduction in the recurrence rate and significant enhancement of the inter-recurrent time during the 9 months of treatment and subsequent 6-month follow-up period. An obvious clinical improvement was accompanied with an induction of an antigen-specific response to HCV1gD and a normalization of reduced mitogenic responsiveness of mono-nuclear cells. According to long-term survey data (on average 48 months after the beginning of therapy), 87% of respondents reported the decreased incidence of recurrent infection. At this time, most patients (85.7%) responded to HCV1gD stimulation. The data obtained suggests that dendritic cell vaccines may be a promising new approach for the treatment of recurrent labial herpes.
[Mh] Termos MeSH primário: Células Dendríticas/imunologia
Herpes Labial/terapia
Vacinas contra o Vírus do Herpes Simples/imunologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Feminino
Vacinas contra o Vírus do Herpes Simples/administração & dosagem
Seres Humanos
Masculino
Meia-Idade
Projetos Piloto
Prevenção Secundária
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Herpes Simplex Virus Vaccines)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171112
[Lr] Data última revisão:
171112
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160917
[St] Status:MEDLINE
[do] DOI:10.1080/21645515.2016.1214348


  5 / 231 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27580249
[Au] Autor:Dutton JL; Woo WP; Chandra J; Xu Y; Li B; Finlayson N; Griffin P; Frazer IH
[Ad] Endereço:a Admedus Vaccines Pty Ltd (formerly Coridon Pty Ltd) , Translational Research Institute , Woolloongabba , QLD , Australia.
[Ti] Título:An escalating dose study to assess the safety, tolerability and immunogenicity of a Herpes Simplex Virus DNA vaccine, COR-1.
[So] Source:Hum Vaccin Immunother;12(12):3079-3088, 2016 12.
[Is] ISSN:2164-554X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:This paper describes a single site, open-label Phase I clinical trial evaluating the safety, tolerability and immunogenicity in healthy volunteers of a herpes simplex polynucleotide vaccine that has previously been shown to enhance immunogenicity and protect against lethal herpes simplex virus type 2 (HSV-2) challenge in mice. Five escalating doses of the vaccine, COR-1, were given by intradermal injection to HSV-1 and 2 seronegative healthy individuals. COR-1 was found to be safe and well-tolerated; the only vaccine-related adverse events were mild. While vaccine-induced antibody responses were not detectable, cell-mediated immune responses to HSV-specific peptide groups were identified in 19 of the 20 subjects who completed the study, and local inflammation at the immunisation site was observed. This study indicates COR-1 has potential to be used as a therapeutic vaccine for HSV-2 infection.
[Mh] Termos MeSH primário: Vacinas contra o Vírus do Herpes Simples/efeitos adversos
Vacinas contra o Vírus do Herpes Simples/imunologia
Herpes Simples/prevenção & controle
Herpesvirus Humano 2/imunologia
Vacinas de DNA/efeitos adversos
Vacinas de DNA/imunologia
[Mh] Termos MeSH secundário: Adulto
Anticorpos Antivirais/sangue
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/epidemiologia
Feminino
Vacinas contra o Vírus do Herpes Simples/administração & dosagem
Seres Humanos
Injeções Intradérmicas
Leucócitos Mononucleares/imunologia
Masculino
Vacinas de DNA/administração & dosagem
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE I; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Viral); 0 (Herpes Simplex Virus Vaccines); 0 (Vaccines, DNA)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171112
[Lr] Data última revisão:
171112
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160901
[St] Status:MEDLINE
[do] DOI:10.1080/21645515.2016.1221872


  6 / 231 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:27110813
[Au] Autor:Önnheim K; Ekblad M; Görander S; Bergström T; Liljeqvist JÅ
[Ad] Endereço:Section of Virology, Department of Infectious Medicine, Institute of Biomedicine, The Sahlgrenska Academy, University of Gothenburg, Guldhedsgatan 10 B, S-413 46 Gothenburg, Sweden. karin.onnheim@gu.se.
[Ti] Título:Vaccination with the Secreted Glycoprotein G of Herpes Simplex Virus 2 Induces Protective Immunity after Genital Infection.
[So] Source:Viruses;8(4):110, 2016 Apr 22.
[Is] ISSN:1999-4915
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Herpes simplex virus 2 (HSV-2) infects the genital mucosa and establishes a life-long infection in sensory ganglia. After primary infection HSV-2 may reactivate causing recurrent genital ulcerations. HSV-2 infection is prevalent, and globally more than 400 million individuals are infected. As clinical trials have failed to show protection against HSV-2 infection, new vaccine candidates are warranted. The secreted glycoprotein G (sgG-2) of HSV-2 was evaluated as a prophylactic vaccine in mice using two different immunization and adjuvant protocols. The protocol with three intramuscular immunizations combining sgG-2 with cytosine-phosphate-guanine dinucleotide (CpG) motifs and alum induced almost complete protection from genital and systemic disease after intra-vaginal challenge with HSV-2. Robust immunoglobulin G (IgG) antibody titers were detected with no neutralization activity. Purified splenic CD4+ T cells proliferated and produced interferon-γ (IFN-γ) when re-stimulated with the antigen in vitro. sgG-2 + adjuvant intra-muscularly immunized mice showed a significant reduction of infectious HSV-2 and increased IFN-γ levels in vaginal washes. The HSV-2 DNA copy numbers were significantly reduced in dorsal root ganglia, spinal cord, and in serum at day six or day 21 post challenge. We show that a sgG-2 based vaccine is highly effective and can be considered as a novel candidate in the development of a prophylactic vaccine against HSV-2 infection.
[Mh] Termos MeSH primário: Glicoproteínas/imunologia
Herpes Genital/prevenção & controle
Vacinas contra o Vírus do Herpes Simples/imunologia
Herpesvirus Humano 2/imunologia
Proteínas Virais/imunologia
[Mh] Termos MeSH secundário: Adjuvantes Imunológicos
Animais
Anticorpos Neutralizantes/sangue
Anticorpos Neutralizantes/imunologia
Anticorpos Antivirais/sangue
Anticorpos Antivirais/imunologia
Antígenos Virais/imunologia
Linhagem Celular
Cercopithecus aethiops
Modelos Animais de Doenças
Feminino
Glicoproteínas/administração & dosagem
Herpes Genital/virologia
Imunização
Interferon gama/biossíntese
Ativação Linfocitária/imunologia
Camundongos
Linfócitos T/imunologia
Linfócitos T/metabolismo
Carga Viral
Proteínas Virais/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Adjuvants, Immunologic); 0 (Antibodies, Neutralizing); 0 (Antibodies, Viral); 0 (Antigens, Viral); 0 (Glycoproteins); 0 (Herpes Simplex Virus Vaccines); 0 (US4 protein, human herpesvirus 2); 0 (Viral Proteins); 82115-62-6 (Interferon-gamma)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160426
[St] Status:MEDLINE


  7 / 231 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27030264
[Au] Autor:Royer DJ; Gurung HR; Jinkins JK; Geltz JJ; Wu JL; Halford WP; Carr DJ
[Ad] Endereço:Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
[Ti] Título:A Highly Efficacious Herpes Simplex Virus 1 Vaccine Blocks Viral Pathogenesis and Prevents Corneal Immunopathology via Humoral Immunity.
[So] Source:J Virol;90(11):5514-29, 2016 Jun 01.
[Is] ISSN:1098-5514
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:UNLABELLED: Correlates of immunologic protection requisite for an efficacious herpes simplex virus 1 (HSV-1) vaccine remain unclear with respect to viral pathogenesis and clinical disease. In the present study, mice were vaccinated with a novel avirulent, live attenuated virus (0ΔNLS) or an adjuvanted glycoprotein D subunit (gD-2) similar to that used in several human clinical trials. Mice vaccinated with 0ΔNLS showed superior protection against early viral replication, neuroinvasion, latency, and mortality compared to that of gD-2-vaccinated or naive mice following ocular challenge with a neurovirulent clinical isolate of HSV-1. Moreover, 0ΔNLS-vaccinated mice exhibited protection against ocular immunopathology and maintained corneal mechanosensory function. Vaccinated mice also showed suppressed T cell activation in the draining lymph nodes following challenge. Vaccine efficacy correlated with serum neutralizing antibody titers. Humoral immunity was identified as the correlate of protection against corneal neovascularization, HSV-1 shedding, and latency through passive immunization. Overall, 0ΔNLS affords remarkable protection against HSV-1-associated ocular sequelae by impeding viral replication, dissemination, and establishment of latency. IMPORTANCE: HSV-1 manifests in a variety of clinical presentations ranging from a rather benign "cold sore" to more severe forms of infection, including necrotizing stromal keratitis and herpes simplex encephalitis. The present study was undertaken to evaluate a novel vaccine to ocular HSV-1 infection not only for resistance to viral replication and spread but also for maintenance of the visual axis. The results underscore the necessity to reconsider strategies that utilize attenuated live virus as opposed to subunit vaccines against ocular HSV-1 infection.
[Mh] Termos MeSH primário: Córnea/patologia
Vacinas contra o Vírus do Herpes Simples/imunologia
Herpesvirus Humano 1/imunologia
Imunidade Humoral
Ceratite Herpética/imunologia
Ceratite Herpética/prevenção & controle
[Mh] Termos MeSH secundário: Animais
Anticorpos Neutralizantes/sangue
Anticorpos Antivirais/sangue
Córnea/imunologia
Córnea/virologia
Feminino
Vacinas contra o Vírus do Herpes Simples/administração & dosagem
Herpesvirus Humano 1/patogenicidade
Seres Humanos
Imunização Passiva
Ceratite Herpética/virologia
Ativação Linfocitária
Camundongos
Vacinas Atenuadas/administração & dosagem
Vacinas Atenuadas/imunologia
Proteínas do Envelope Viral/administração & dosagem
Proteínas do Envelope Viral/imunologia
Eliminação de Partículas Virais
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Neutralizing); 0 (Antibodies, Viral); 0 (Herpes Simplex Virus Vaccines); 0 (Vaccines, Attenuated); 0 (Viral Envelope Proteins); 0 (glycoprotein D, Human herpesvirus 1)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170428
[Lr] Data última revisão:
170428
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160401
[St] Status:MEDLINE
[do] DOI:10.1128/JVI.00517-16


  8 / 231 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26973067
[Au] Autor:Johnston C; Gottlieb SL; Wald A
[Ad] Endereço:Department of Medicine, Seattle, WA, USA; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Electronic address: cjohnsto@u.washington.edu.
[Ti] Título:Status of vaccine research and development of vaccines for herpes simplex virus.
[So] Source:Vaccine;34(26):2948-2952, 2016 Jun 03.
[Is] ISSN:1873-2518
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Herpes simplex virus type-1 (HSV-1) and -2 (HSV-2) are highly prevalent global pathogens which commonly cause recurrent oral and genital ulcerations. Less common but more serious complications include meningitis, encephalitis, neonatal infection, and keratitis. HSV-2 infection is a significant driver of the HIV epidemic, increasing the risk of HIV acquisition 3 fold. As current control strategies for genital HSV-2 infection, including antiviral therapy and condom use, are only partially effective, vaccines will be required to reduce infection. Both preventive and therapeutic vaccines for HSV-2 are being pursued and are in various stages of development. We will provide an overview of efforts to develop HSV-2 vaccines, including a discussion of the clinical need for an HSV vaccine, and status of research and development with an emphasis on recent insights from trials of vaccine candidates in clinical testing. In addition, we will touch upon aspects of HSV vaccine development relevant to low and middle income countries.
[Mh] Termos MeSH primário: Vacinas contra o Vírus do Herpes Simples/uso terapêutico
Herpes Simples/prevenção & controle
[Mh] Termos MeSH secundário: Animais
Pesquisa Biomédica/tendências
Ensaios Clínicos como Assunto
Herpesvirus Humano 1
Herpesvirus Humano 2
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Herpes Simplex Virus Vaccines)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171019
[Lr] Data última revisão:
171019
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160315
[St] Status:MEDLINE


  9 / 231 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26897058
[Au] Autor:Birkmann A; Zimmermann H
[Ad] Endereço:AiCuris Anti-infective Cures GmbH, Germany.
[Ti] Título:HSV antivirals - current and future treatment options.
[So] Source:Curr Opin Virol;18:9-13, 2016 Jun.
[Is] ISSN:1879-6265
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Herpes simplex virus (HSV) types 1 and 2 can cause infections with clinical manifestations ranging from benign and generally self-limiting blisters or sores as seen in labial and genital herpes through to severe and in rare cases even life-threatening infections. At present, approved treatments for herpes simplex virus are almost all nucleoside analogs. Novel antiviral approaches include therapeutic vaccines, with the most advanced having successfully completed Phase 2 clinical development. Moreover, several small molecules approaches are being developed for the treatment of genital or labial HSV infections. Of particular interest are two novel compounds (amenamevir and pritelivir) belonging to the new class of helicase-primase inhibitors with promising Phase 2 data.
[Mh] Termos MeSH primário: Antivirais/uso terapêutico
Herpes Genital/tratamento farmacológico
Herpes Simples/tratamento farmacológico
Herpes Simples/virologia
[Mh] Termos MeSH secundário: Aciclovir/efeitos adversos
Aciclovir/farmacologia
Aciclovir/uso terapêutico
Antivirais/administração & dosagem
Ensaios Clínicos Fase II como Assunto
DNA Helicases/antagonistas & inibidores
DNA Primase/antagonistas & inibidores
Farmacorresistência Viral
Herpes Genital/virologia
Herpes Simples/prevenção & controle
Vacinas contra o Vírus do Herpes Simples/administração & dosagem
Vacinas contra o Vírus do Herpes Simples/efeitos adversos
Vacinas contra o Vírus do Herpes Simples/uso terapêutico
Herpesvirus Humano 1/efeitos dos fármacos
Herpesvirus Humano 2/efeitos dos fármacos
Seres Humanos
Oxidiazóis/efeitos adversos
Oxidiazóis/uso terapêutico
Piridinas/efeitos adversos
Piridinas/uso terapêutico
Tiazóis/efeitos adversos
Tiazóis/uso terapêutico
Proteínas Virais/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (ASP2151); 0 (Antiviral Agents); 0 (BAY 57-1293); 0 (Herpes Simplex Virus Vaccines); 0 (Oxadiazoles); 0 (Pyridines); 0 (Thiazoles); 0 (Viral Proteins); EC 2.7.7.- (DNA Primase); EC 3.6.4.- (DNA Helicases); X4HES1O11F (Acyclovir)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171020
[Lr] Data última revisão:
171020
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160222
[St] Status:MEDLINE


  10 / 231 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26896782
[Au] Autor:Kaufmann JK; Flechtner JB
[Ad] Endereço:Genocea Biosciences Inc., Cambridge Discovery Park, 100 Acorn Park Drive, Cambridge, MA 02140, USA. Electronic address: johanna.kaufmann@genocea.com.
[Ti] Título:Evolution of rational vaccine designs for genital herpes immunotherapy.
[So] Source:Curr Opin Virol;17:80-6, 2016 Apr.
[Is] ISSN:1879-6265
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Immunotherapeutic vaccines have emerged as a novel treatment modality for genital herpes, a sexually transmitted disease mainly caused by herpes simplex virus type 2. The approaches to identify potential vaccine antigens have evolved from classic virus attenuation and characterization of antibody and T cell responses in exposed, but seronegative individuals, to systematic screens for novel T cell antigens. Combined with implementation of novel vaccine concepts revolving around immune evasion and local recruitment of immune effectors, the development of a safe and effective therapeutic vaccine is within reach. Here, we describe the vaccine approaches that currently show promise at clinical and pre-clinical stages and link them to the evolving scientific strategies that led to their identification.
[Mh] Termos MeSH primário: Herpes Genital/terapia
Vacinas contra o Vírus do Herpes Simples/imunologia
Herpesvirus Humano 2/imunologia
Imunoterapia/métodos
[Mh] Termos MeSH secundário: Animais
Anticorpos Neutralizantes/sangue
Anticorpos Neutralizantes/imunologia
Anticorpos Antivirais/sangue
Anticorpos Antivirais/imunologia
Ensaios Clínicos como Assunto
Desenho de Drogas
Descoberta de Drogas
Herpes Genital/imunologia
Herpes Genital/virologia
Vacinas contra o Vírus do Herpes Simples/administração & dosagem
Seres Humanos
Evasão da Resposta Imune
Camundongos
Linfócitos T/imunologia
Proteínas do Envelope Viral/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antibodies, Neutralizing); 0 (Antibodies, Viral); 0 (Herpes Simplex Virus Vaccines); 0 (Viral Envelope Proteins)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171019
[Lr] Data última revisão:
171019
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160221
[St] Status:MEDLINE



página 1 de 24 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde